A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Greenfield, William W ^a   Stratton, Shawna L ^b   Myrick, Rebecca S ^b   Vaughn, Rita ^b   Donnalley, Lisa M ^b   Coleman, Hannah N ^b   Mercado, Maria ^b   Moerman Herzog, Andrea M ^b   Spencer, Horace J ^b   Andrews Collins, Nancy R ^a   Hitt, Wilbur C ^a   Low, Gordon M ^a   Manning, Nirvana A ^a   McKelvey, Samantha S ^a   Smith, Dora ^a   Smith, Michael V ^a   Phillips, Amy M ^a   Quick, C Matthew ^b   Jeffus, Susanne K ^b   Hutchins, Laura F ^a   Nakagawa, Mayumi ^b   more..

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

cervical intraepithelial neoplasia; clinical trial; human papillomavirus; T cells; therapeutic vaccine

Indexed keywords

CANDIDA SKIN TEST REAGENT; GAMMA GLUTAMYLTRANSFERASE; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; PLACEBO; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADULT; AGITATION; ARTICLE; CANCER GRADING; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HISTOLOGY; HOT FLUSH; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MIDDLE AGED; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; REGULATORY T LYMPHOCYTE; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VERTIGO; VOMITING; WART VIRUS; YOUNG ADULT;

EID: 84940705559     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1031439     Document Type: Article

References (49)

1. Cancer IAfRo. GLOBOCAN 2012 CANCER FACT SHEET. Cedex, France, 2012.
2. A.K.Chaturvedi. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010; 46:S20-6; PMID:20307840; http://dx.doi.org/10.1016/j.jadohealth.2010.01.016
3. J.E.Tota, M.Chevarie-Davis, L.A.Richardson, M.Devries, E.L.Franco. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011; 53 Suppl 1:S12-21; PMID:21962466; http://dx.doi.org/10.1016/j.ypmed.2011.08.017
4. F.J.Bruinsma, M.A.Quinn. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 2011; 118:1031-41; PMID:21449928; http://dx.doi.org/10.1111/j.1471-0528.2011.02944.x
5. L.S.Massad, M.H.Einstein, W.K.Huh, H.A.Katki, W.K.Kinney, M.Schiffman, D.Solomon, N.Wentzensen, H.W.Lawson. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121:829-46; PMID:23635684; http://dx.doi.org/10.1097/AOG.0b013e3182883a34
6. V.Kumar, N.Fausto, A.Abbas. Cervix. Robbins & Cotran Pathologic Basis of Disease, 2004:1072-9
7. L.Pirisi, S.Yasumoto, M.Feller, J.Doniger, J.DiPaolo. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol l987; 61:1061-6; PMID: 2434663.
8. R.Schlegel, W.C.Phelps, Y.L.Zhang, M.Barbosa. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. Embo J 1988; 7:3181-7; PMID:2460337
9. M.Nakagawa, D.P.Stites, S.Patel, S.Farhat, M.Scott, N.K.Hills, J.M.Palefsky, A.B.Moscicki. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182:595-8; PMID:10915094; http://dx.doi.org/10.1086/315706
10. K.H.Kim, W.W.Greenfield, M.J.Cannon, H.N.Coleman, H.J.Spencer, M.Nakagawa. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother 2012; 61:63-70; PMID:21842207; http://dx.doi.org/10.1007/s00262-011-1092-5
11. M.Nakagawa, S.K.Gupta, H.N.Coleman, M.A.Sellers, J.A.Banken, W.W.Greenfield. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis 2010; 14:124-9; PMID:20354421; http://dx.doi.org/10.1097/LGT.0b013e3181c6f01e
12. R.E.Esch, C.E.Buckley,, 3rd. A novel Candida albicans skin test antigen: efficacy and safety in man. J Biol Stand 1988; 16:33-43; PMID:3280571; http://dx.doi.org/10.1016/0092-1157(88)90027-3
13. M.M.Clifton, S.M.Johnson, P.K.Roberson, J.Kincannon, T.D.Horn. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol 2003; 20:268-71; PMID:12787281; http://dx.doi.org/10.1046/j.1525-1470.2003.20318.x
14. T.D.Horn, S.M.Johnson, R.M.Helm, P.K.Roberson. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol 2005; 141:589-94; PMID:15897380; http://dx.doi.org/10.1001/archderm.141.5.589
15. S.M.Johnson, P.K.Roberson, T.D.Horn. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 2001; 137:451-5; PMID:11295925
16. K.H.Kim, T.D.Horn, J.Pharis, J.Kincannon, R.Jones, K.O'Bryan, J.Myers, M.Nakagawa. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol 2010; 146:1431-3; PMID:21173332; http://dx.doi.org/10.1001/archdermatol.2010.350
17. M.L.Bagarazzi, J.Yan, M.P.Morrow, X.Shen, R.L.Parker, J.C.Lee, M.Giffear, P.Pankhong, A.S.Khan, K.E.Broderick et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra38; PMID: 23052295; http://dx.doi.org/10.1126/scitranslmed.3004414
18. G.G.Kenter, M.J.Welters, A.R.Valentijn, M.J.Lowik, D.M.Berends-van der Meer, A.P.Vloon, F.Essahsah, L.M.Fathers, R.Offringa, J.W.Drijfhout et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx.doi.org/10.1056/NEJMoa0810097
19. S.Daayana, E.Elkord, U.Winters, M.Pawlita, R.Roden, P.L.Stern, H.C.Kitchener. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010; 102:1129-36; PMID:20234368; http://dx.doi.org/10.1038/sj.bjc.6605611
20. M.Nakagawa, D.P.Stites, S.Farhat, J.R.Sisler, B.Moss, F.Kong, A.B.Moscicki, J.M.Palefsky. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997; 175:927-31; PMID:9086151; http://dx.doi.org/10.1086/513992
21. X.Wang, H.N.Coleman, U.Nagarajan, H.J.Spencer, M.Nakagawa. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine 2013; 31:5806-13; PMID:24135577; http://dx.doi.org/10.1016/j.vaccine.2013.10.014
22. A.K.Abbas, A.H.Lichtman, S.Pillai. Cellular and Molecular Immunology. Philadelphia: Elsevier, 2011.
23. P.Nieminen, D.M.Harper, M.H.Einstein, F.Garcia, G.Donders, W.Huh, T.C.Wright, M.Stoler, A.Ferenczy, O.Rutman et al. Efficacy and safety of RO5217990 treatment in patients with high grade cervical intraepithelial neoplasia (CIN2/3). 28th International Papillomavirus Conference. Puerto Rico, 2012; Clinical Science Abstract Book; p. 206.
24. A.Ribas, J.M.Timmerman, L.H.Butterfield, J.S.Economou. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003; 24:58-61; PMID:12547500; http://dx.doi.org/10.1016/S1471-4906(02)00029-7
25. L.Bruni, M.Diaz, X.Castellsague, E.Ferrer, F.X.Bosch, S.de Sanjose. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202:1789-99; PMID:21067372; http://dx.doi.org/10.1086/657321
26. G.M.Clifford, S.Gallus, R.Herrero, N.Munoz, P.J.Snijders, S.Vaccarella, P.T.Anh, C.Ferreccio, N.T.Hieu, E.Matos et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-8; PMID:16168781; http://dx.doi.org/10.1016/S0140-6736(05)67069-9
27. G.M.Clifford, J.S.Smith, M.Plummer, N.Munoz, S.Franceschi. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88:63-73; PMID:12556961; http://dx.doi.org/10.1038/sj.bjc.6600688
28. N.Munoz, F.X.Bosch, S.de Sanjose, R.Herrero, X.Castellsague, K.V.Shah, P.J.Snijders, C.J.Meijer. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641
29. J.S.Smith, L.Lindsay, B.Hoots, J.Keys, S.Franceschi, R.Winer, G.M.Clifford. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-32; PMID:17405118; http://dx.doi.org/10.1002/ijc.22527
30. M.van den Hende, A.Redeker, K.M.Kwappenberg, K.L.Franken, J.W.Drijfhout, J.Oostendorp, A.R.Valentijn, L.M.Fathers, M.J.Welters, C.J.Melief et al. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. J Infect Dis 2010; 202:1200-11; PMID:20822453; http://dx.doi.org/10.1086/656367
31. C.L.Slingluff, Jr, G.R.Petroni, W.C.Olson, M.E.Smolkin, M.I.Ross, N.B.Haas, W.W.Grosh, M.E.Boisvert, J.M.Kirkwood, K.A.Chianese-Bullock. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15:7036-44; PMID:19903780; http://dx.doi.org/10.1158/1078-0432.CCR-09-1544
32. M.Nakagawa, H.N.Coleman, X.Wang, J.Daniels, J.Sikes, U.M.Nagarajan. IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine 2014; 65:202-9; PMID:24301038; http://dx.doi.org/10.1016/j.cyto.2013.11.002
33. R.Manetti, P.Parronchi, M.G.Giudizi, M.P.Piccinni, E.Maggi, G.Trinchieri, S.Romagnani. Natural killer cell stimulatory factor (interleukin 12 ; IL-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199--204; PMID:8096238; http://dx.doi.org/10.1084/jem.177.4.1199
34. C.S.Hsieh, S.E.Macatonia, C.S.Tripp, S.F.Wolf, A.O'Garra, K.M.Murphy. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9; PMID:8097338; http://dx.doi.org/10.1126/science.8097338
35. S.Tugues, S.H.Burkhard, I.Ohs, M.Vrohlings, K.Nussbaum, J.Vom Berg, P.Kulig, B.Becher. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2014; PMID:25190142; http://dx.doi.org/10.1038.cdd.2014-134
36. D.Berd, H.C.Maguire, Jr, M.J.Mastrangelo. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44:5439-43; PMID:6488195
37. A.Emadi, R.J.Jones, R.A.Brodsky. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6:638-47; PMID:19786984; http://dx.doi.org/10.1038/nrclinonc.2009.146
38. A.Hildesheim, M.Schiffman, D.R.Scott, D.Marti, T.Kissner, M.E.Sherman, A.G.Glass, M.M.Manos, A.T.Lorincz, R.J.Kurman et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998; 7:1035-41; PMID:9829713
39. M.M.Madeleine, L.G.Johnson, A.G.Smith, J.A.Hansen, B.B.Nisperos, S.Li, L.P.Zhao, J.R.Daling, S.M.Schwartz, D.A.Galloway. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 2008; 68:3532-9; PMID:18451182; http://dx.doi.org/10.1158/0008-5472.CAN-07-6471
40. S.S.Wang, C.M.Wheeler, A.Hildesheim, M.Schiffman, R.Herrero, M.C.Bratti, M.E.Sherman, M.Alfaro, M.L.Hutchinson, J.Morales et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001; 184:1310-4; PMID:11679920; http://dx.doi.org/10.1086/324209
41. K.H.Kim, R.Dishongh, A.D.Santin, M.J.Cannon, S.Bellone, M.Nakagawa. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun 2006; 6:9; PMID:16808432
42. X.Wang, W.W.Greenfield, H.N.Coleman, L.E.James, M.Nakagawa. Use of interferon-gamma enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus. J Vis Exp 2012; PMID: 22434036; http://dx.doi.org/10.3791/3657
43. M.Nakagawa, K.H.Kim, A.B.Moscicki. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol 2005; 12:1003-5; PMID:16085919
44. M.Nakagawa, K.H.Kim, T.M.Gillam, A.B.Moscicki. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol 2007; 81:1412-23; PMID:17108051; http://dx.doi.org/10.1128/JVI.01768-06
45. X.Wang, A.B.Moscicki, L.Tsang, A.Brockman, M.Nakagawa. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol 2008; 15:937-45; PMID:18448624; http://dx.doi.org/10.1128/CVI.00404-07
46. R.Kaul, T.Dong, F.A.Plummer, J.Kimani, T.Rostron, P.Kiama, E.Njagi, E.Irungu, B.Farah, J.Oyugi et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-10; PMID:11375420; http://dx.doi.org/10.1172/JCI12433
47. A.Kobayashi, V.Weinberg, T.Darragh, K.Smith-McCune. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008; 1:412-20; PMID:19079205; http://dx.doi.org/10.1038/mi.2008.33
48. T.Magg, J.Mannert, J.W.Ellwart, I.Schmid, M.H.Albert. Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells. Eur J Immunol 2012; 42:1627-38; PMID:22678915; http://dx.doi.org/10.1002/eji.201141838
49. OrganProcurementandTransplantationNetwork. US-Department of Health & Human Services.